NIH Seeks Feedback on Customer Surveys
Published Date: 7/8/2026
Notice
Summary
The NIH wants your feedback on a plan to collect info about how people use and feel about their programs, products, and services. This helps NIH improve what they offer without making it a hassle for you. Comments are open until August 7, 2026, so jump in and share your thoughts to help shape the future!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
2026-13612 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important health research grant applications. These meetings keep sensitive info private to protect personal and commercial secrets. Researchers applying for grants and the public can expect no changes in funding timing or amounts, just careful, confidential reviews.
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
2026-13337 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on July 24, 2026, to review and evaluate important grant applications related to cancer, imaging, eye diseases, and reproductive health. These meetings protect private info and trade secrets, so they’re not open to the public. Researchers and organizations applying for grants should note the dates as these reviews impact funding decisions.
2026-13311 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review grant applications and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants or contracts should watch these dates closely, as funding decisions could impact their projects and budgets.
Previous / Next Documents
Previous: 2026-13804 — Submission for Review: 3206-NEW, Request for Reduction or Cancellation of Federal Employees Group Life Insurance (FEGLI), RI 76-30
Federal employees who want to reduce or cancel their Group Life Insurance (FEGLI) now have a new form to make it easier. The Office of Personnel Management is asking for public feedback on this new form until August 7, 2026. This update aims to simplify the process without changing costs or coverage timing.
Next: 2026-13810 — Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec
The FDA is holding a public meeting on July 30, 2026, to review a new medicine called Vusolimogene Oderparepvec from Replimune, Inc. This meeting lets experts and the public share their thoughts before the FDA decides if the medicine should be approved. Anyone interested has until July 29 to send in their comments, making this a big chance to help shape new treatments!